Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Interest & Investment Income of $26.6 million for Q1 2026, down 75.74% on a QoQ basis from $109.7 million in Q4 2025, and up 2482.33% year-over-year from $1.0 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at $26.6 million for Q1 2026.
- Quarterly Interest & Investment Income rose 2482.33% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.0 million (up 239.2% YoY) and the FY2025 annual result came in at $111.5 million, down 8.63% from the prior year.
- Interest & Investment Income was $26.6 million for Q1 2026 at Alnylam Pharmaceuticals, down from $109.7 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $109.7 million in Q4 2025 and bottomed at -$7.2 million in Q1 2022.
- A 5-year average of $14.0 million and a median of $3.2 million in 2022 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 12318.75% in 2022, while the deepest fall reached 721600.0% in 2022.
- Alnylam Pharmaceuticals' Interest & Investment Income stood at $3.2 million in 2022, then soared by 122.5% to $7.0 million in 2023, then jumped by 340.61% to $31.0 million in 2024, then surged by 253.5% to $109.7 million in 2025, then tumbled by 75.74% to $26.6 million in 2026.
- Business Quant data shows ALNY's Interest & Investment Income at $26.6 million in Q1 2026, $109.7 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 26.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.60 Mn |
| Dec 31, 2025 | 109.65 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | -343,000.00 |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | 31.02 Mn |
| Sep 30, 2024 | 9.08 Mn |
| Jun 30, 2024 | -727,000.00 |
| Mar 31, 2024 | 29.65 Mn |
| Dec 31, 2023 | 7.04 Mn |
| Sep 30, 2023 | 1.88 Mn |
| Jun 30, 2023 | -2.03 Mn |
| Mar 31, 2023 | 18.66 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 7.82 Mn |
| Jun 30, 2022 | 1.90 Mn |
| Mar 31, 2022 | -7.22 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | -64,000.00 |
| Jun 30, 2021 | -247,000.00 |